Committee for Medicinal Products for Human Use (CHMP)
“In Europe, the EMA’s main task is to evaluate new drugs and medical devices before they become available on the market. It has three committees: one for medicinal products for human use (CHMP), one for cosmetics and personal care products (CPMP), and one for veterinary medicine (CVMP).”
Conducting an initial assessment of European Union (EU) market authorization applications
- Assessing whether changes or additions to an existing marketing authorization would be appropriate;
- Considering the recommendation of the Agency’ s Pharmacovigilance Risk Assessments Committee (PRAC) on the safety of medicines already on the market, and when necessary, suggesting to the European Commission changes for a medicine’s approval, or its suspension or removal from the market.
More information about Committee for Medicinal Products for Human Use (CHMP)
Approval,positive opinion,meeting,medicine,Committee,treatment,product,authorisation,List itemRecommendations,List itemScientific.
Orphan medicine,Committee for Orphan Medicinal Products,human medicines committee,medicines for approval,time of approval,itemScientific advice,opinion,disease,extensions of indication.
ItemRecommendations on eligibility,Orphan designations,orphan status,protocol assistance,vaccines,Committee for Medicinal Products for Human Use,conditional marketing authorisation,Europe,review,infection,risk,cell,Ireland,antibodies,clinical trials,public health communication,human medicines,generic medicines,indication for medicines,marketing authorisations,treatment of adults,white blood cell.
Reference product,procedures,negative opinion,applicant,gene,studies,vaccination,supplemental oxygen,visual impairment,exceptional circumstances,PRIority MEdicines,meeting highlights,list,List itemOverview,COVID-19 vaccine,hybrid medicine,Committee for Advanced Therapies,Committee for Proprietary Medicinal Products,committee responsible,application for marketing authorisation,marketing authorisation holder,authorisation holderPfizer,treatment of adult patients,non-small cell lung cancer,plasma cells,potential approvals,-Myers Squibb Pharma,holderBristol-Myers Squibb Pharma,Prevention Pharma,Marketing-authorisation applicant,Europe BVTherapeutic,Sciences Ireland,cold agglutinin disease,respiratory tract disease,Europharm LimitedMore,risk factors,primary vaccination,18-21 July,bone marrow,choroidal neovascularisation,diabetic retinopathy,fallopian tube,haemolytic anaemia,holderAbbVie Deutschland GmbH &,macular oedema,medicineOpdivoINNnivolumabMarketing-authorisation holderBristol,opinions on questions concerning,scientific evaluation,severe COVID-19,Sharp & Dohme,blood cancer,Marketing-authorisation holder,Hybrid applications,17-20 May,AstraZeneca AB,11-14 November 2019 meeting,11-14 October 2021 meeting,12-15 October 2020 meeting,13-16 December 2021 meeting,13-16 September 2021 meeting,14-17 October 2019 meeting,14-17 September 2020 meeting,16-19 August 2021 meeting,16-19 September 2019 meeting,17-20 May 2021 meeting,19-22 April 2021 meeting,19-22 July 2021 meeting,20-23 July 2020 meeting,21-24 June 2021 meeting,22-25 February 2021 meeting,22-25 July 2019 meeting,22-25 June 2020 meeting,22-25 March 2021 meeting,23-26 April 2019 meeting,23-26 March 2020 meeting,24-27 February 2020 meeting,24-27 June 2019 meeting,”25-28 February 2019,CHMP meeting”,25-28 February 2019 meeting,25-28 March 2019 meeting,25-28 May 2020 meeting,25-29 January 2021 meeting,27-29 May 2019 meeting,27-30 January 2020 meeting,28-30 April 2020 meeting,28-31 January 2019 meeting,”7-10 December 2020,CHMP meeting”,7-10 December 2020 meeting,8-11 November 2021 meeting,9-12 December 2019 meeting,9-12 November 2020 meeting,List itemMinutes,List itemAgenda – CHMP agenda,List itemCHMP ORGAM agenda,List itemCHMP ORGAM minutes,List itemCHMP PROM agenda,List itemCHMP PROM minutes,Company’s COVID-19 Vaccine,trivalent influenza vaccine,Vaccine AstraZeneca,vaccine in adolescents ages,”24/06/2022EMA/598738/2022,COVID-19 Vaccine”,adenoviral vector vaccine,antiviral medicine,add-on treatment,antiviral treatment,cell lymphoma,regulatory approval,product candidates,medicinal product,17-20 August 2020 written procedure,19-22 August 2019 written procedure,administration procedure,additional advice,advice on blood clots,advice to companies researching,Pharma A/SMore,respective applicant,Alexion Europe SAS,gene therapy,AGIL-AADC gene therapy results,alafenamideMarketing-authorisation holderGilead Sciences Ireland,19357527 Review,29958099 Review,hydrochlorideMarketing-authorisation holderNovartis Europharm LimitedMore information,LimitedMore,complications of infection,adults with cytomegalovirus infection,persons at risk,clinical studies,additional studies,adolescents after vaccination,antibody positive,anti-CD38 antibody.